These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27057831)

  • 1. Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea.
    Park B; Choi JY; Sung HK; Ahn C; Hwang Y; Jang J; Lee J; Kim H; Shin HR; Park S; Han W; Noh DY; Yoo KY; Kang D; Park SK
    Medicine (Baltimore); 2016 Apr; 95(14):e3063. PubMed ID: 27057831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.
    Kwan ML; Kushi LH; Weltzien E; Maring B; Kutner SE; Fulton RS; Lee MM; Ambrosone CB; Caan BJ
    Breast Cancer Res; 2009; 11(3):R31. PubMed ID: 19463150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.
    Ma H; Wang Y; Sullivan-Halley J; Weiss L; Marchbanks PA; Spirtas R; Ursin G; Burkman RT; Simon MS; Malone KE; Strom BL; McDonald JA; Press MF; Bernstein L
    Cancer Res; 2010 Jan; 70(2):575-87. PubMed ID: 20068186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea.
    Lee JS; Oh M; ;
    Clin Breast Cancer; 2014 Dec; 14(6):426-34. PubMed ID: 25034438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
    Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.
    de Macêdo Andrade AC; Ferreira Júnior CA; Dantas Guimarães B; Pessoa Barros AW; Sarmento de Almeida G; Weller M
    BMC Womens Health; 2014 Sep; 14():110. PubMed ID: 25216732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.
    Xing P; Li J; Jin F
    Med Oncol; 2010 Sep; 27(3):926-31. PubMed ID: 19771534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between common risk factors and molecular subtypes in breast cancer patients.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
    Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
    Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
    Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
    Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
    Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
    Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.
    Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
    Horm Cancer; 2019 Jun; 10(2-3):71-76. PubMed ID: 30989580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
    Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
    Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya.
    Sayed S; Fan S; Moloo Z; Wasike R; Bird P; Saleh M; Shaikh AJ; Figueroa JD; Naidoo R; Makokha FW; Gardner K; Oigara R; Njoroge FW; Magangane P; Mutebi M; Chauhan R; Mwanzi S; Govender D; Yang XR
    Breast Cancer Res; 2021 Jun; 23(1):68. PubMed ID: 34174935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.